A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another area of the body (metastasized).

Trial Details

NCT ID

NCT06290505

Phase

PHASE2

Sponsor

Australasian Gastro-Intestinal Trials Group

Status

RECRUITING

Cancer Type

Esophageal Cancer

Interventions

Durvalumab

Locations (sample)

Garran, Australian Capital Territory, Australia|-35.34206,149.10846
Albury, New South Wales, Australia|-36.07482,146.92401
Newcastle, New South Wales, Australia|-32.92953,151.7801
Herston, Queensland, Australia|-27.44453,153.01852
Bedford Park, South Australia, Australia|-35.02204,138.56815

Key Eligibility Criteria

Males and females \> 18 years of age.
Biopsy proven adenocarcinoma or squamous cell carcinoma of the esophagus or gastro-oesophageal junction
Oligometastatic disease (1-5 lesions outside the primary tumour radiotherapy field on FDG-PET scan), or locoregionally advanced disease unsuitable …
Symptomatic dysphagia (Mellow score greater than 0)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →